LIVIVO - Search results -

Search results

Result 1 - 10 of total 51

Search options

Article: Studio epidemiologico su 1665 casi de neoplasie broncogene raccolte all' Ospedale "S. Luigi Gonzaga" fra il 1973 e il 1979.

Moschini, M T / Cardesi, E / Giorgis, G E / Bardessono, F / Marasso, A

1981 Volume 72, Issue 25, Page(s) 1573–1580

Abstract: Data regarding 1,665 cases of benign and malignant lung cancers are examined and frequency behaviour analysed by histological type, sex, age groups and site of onset. Results are compared with other reported data and it is concluded that there is a ... ...

Title translation	Epidemiologic study of 1665 cases of bronchogenic neoplasms collected at the S. Luigi Gonzaga Hospital between 1973 and 1979.
Abstract	Data regarding 1,665 cases of benign and malignant lung cancers are examined and frequency behaviour analysed by histological type, sex, age groups and site of onset. Results are compared with other reported data and it is concluded that there is a considerable increase in dyskaryokinesis in both sexes, especially females (particularly epidermoid forms), and that there is a shift in maximum incidence towards more advanced age groups. No variation was seen, however, with respect to the frequency of bronchial tree localisation.
MeSH term(s)	Adult ; Age Factors ; Aged ; Bronchi/pathology ; Bronchial Neoplasms/classification ; Bronchial Neoplasms/epidemiology ; Bronchial Neoplasms/pathology ; Female ; Humans ; Italy ; Male ; Middle Aged ; Sex Factors
Language	Italian
Publishing date	1981-06-23
Publishing country	Italy
Document type	Comparative Study ; English Abstract ; Journal Article
ZDB-ID	123586-2
ISSN	1827-1669 ; 0026-4806
ISSN (online)	1827-1669
ISSN	0026-4806
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.132: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Il fenomeno della resistenza primaria del bacillo di Koch: casistica raccolta nell'ospedale pneumologico S. Luigi di Torino dal 1972 al 1975

Briccarello, L / Bardessono, F / Daglio, C / Ferraro, U / Giorgis, G E / Moschini, M T

Giornale di batteriologia, virologia ed immunologia

1976 Volume 69, Issue 1-6, Page(s) 49–59

Abstract: In this work the authors stress the importance reached in recent years by the primary resistance phenomenon in pulmonary consumption, and they explain the results pointed out by the examination of 171 antibiograms effected from 1972 to 1975 on patients ... ...

Title translation	Phenomenon of primary resistance of Koch's bacillus: report on cases assembled at the pneumological hospital S. Luigi in Turin from 1972 to 1975.
Abstract	In this work the authors stress the importance reached in recent years by the primary resistance phenomenon in pulmonary consumption, and they explain the results pointed out by the examination of 171 antibiograms effected from 1972 to 1975 on patients with pathological forms ascertained for the first time. They conclude by underlining the reduction of the primary resistance when employing common antibiotics and, on the contrary, its rise with the use of the rifampicin which has recently been introduced in therapy; lastly they put into evidence the epidemiological importance of the phenomenon itself.
MeSH term(s)	Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Drug Resistance, Microbial ; Hospitals, Special ; Humans ; Italy ; Mycobacterium tuberculosis/drug effects ; Tuberculosis, Pulmonary/drug therapy
Chemical Substances	Antitubercular Agents
Language	Italian
Publishing date	1976-01
Publishing country	Italy
Document type	English Abstract ; Journal Article
ZDB-ID	412749-3
ISSN	0390-5462 ; 0017-0267
ISSN	0390-5462 ; 0017-0267
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 122: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The modified NUTRIC score (mNUTRIC) is associated with increased 28-day mortality in critically ill COVID-19 patients: Internal validation of a prediction model.

Leoni, Matteo Luigi Giuseppe / Moschini, Elisa / Beretta, Maurizio / Zanello, Marco / Nolli, Massimo

Clinical nutrition ESPEN

2022 Volume 48, Page(s) 202–209

Abstract: Background: High prevalence of malnutrition was found in critically ill COVID-19 patients. The modified Nutrition Risk in the Critically ill (mNUTRIC) score is frequently used for nutritional risk assessment in intensive care unit (ICU) COVID-19 ... ...

Abstract	Background: High prevalence of malnutrition was found in critically ill COVID-19 patients. The modified Nutrition Risk in the Critically ill (mNUTRIC) score is frequently used for nutritional risk assessment in intensive care unit (ICU) COVID-19 patients. The aim of this study was to investigate the role of mNUTRIC score to predict 28-day mortality in critically ill COVID-19 patients admitted to ICU. Methods: A cohort of consecutive COVID-19 critically ill patients admitted to ICU was retrospectively evaluated and the nutritional risk was assessed with the use of mNUTRIC score. A multivariable Cox regression model to predict 28-day mortality was therefore developed including the mNUTRIC as a covariate. Internal validation was performed using the bootstrap resampling technique to reduce possible bias in the estimated risks. The performance of the prediction model was assessed via calibration and discrimination. Results: A total of 98 critically ill COVID-19 patients with a median age of 66 years (56-73 IQR), 81 (82.7%) males were included in this study. A high nutritional risk (mNUTRIC ≥5 points) was observed in 41.8% of our critically ill COVID-19 patients while a low nutritional risk (mNUTRIC <5 points) was observed in 58.2%. Forty-five patients (45.9%) died within 28 days after ICU admission. In multivariable model after internal validation, mNUTRIC ≥5 (optimism adjusted HR 2.38, 95% CI 1.08-5.25, p = 0.02) and high-sensitivity C-reactive protein values (CRP) (optimism adjusted HR 1.02, 95% CI 1.01-1.07, p = 0.005) were independent predictors of 28-day mortality. Conclusions: A high prevalence of malnutrition as revealed by mNUTRIC was found in our critically ill COVID-19 patients once admitted in ICU. After adjustment for covariables, mNUTRIC ≥5 and CRP levels were independently associated with 28-day mortality in critically ill COVID-19 patients. The final model revealed good discrimination and calibration. Nutritional risk assessment is essential for the management of critically ill COVID-19 patients as well as for outcome prediction.
MeSH term(s)	COVID-19 ; Critical Illness ; Humans ; Intensive Care Units ; Male ; Retrospective Studies ; Risk Assessment/methods
Language	English
Publishing date	2022-02-17
Publishing country	England
Document type	Journal Article
ISSN	2405-4577
ISSN (online)	2405-4577
DOI	10.1016/j.clnesp.2022.02.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: The modified NUTRIC score (mNUTRIC) is associated with increased 28-day mortality in critically ill COVID-19 patients: Internal validation of a prediction model

Leoni, Matteo Luigi Giuseppe / Moschini, Elisa / Beretta, Maurizio / Zanello, Marco / Nolli, Massimo

Clinical nutrition ESPEN. 2022 Apr., v. 48

2022

Abstract: High prevalence of malnutrition was found in critically ill COVID-19 patients. The modified Nutrition Risk in the Critically ill (mNUTRIC) score is frequently used for nutritional risk assessment in intensive care unit (ICU) COVID-19 patients. The aim of ...

Abstract	High prevalence of malnutrition was found in critically ill COVID-19 patients. The modified Nutrition Risk in the Critically ill (mNUTRIC) score is frequently used for nutritional risk assessment in intensive care unit (ICU) COVID-19 patients. The aim of this study was to investigate the role of mNUTRIC score to predict 28-day mortality in critically ill COVID-19 patients admitted to ICU. A cohort of consecutive COVID-19 critically ill patients admitted to ICU was retrospectively evaluated and the nutritional risk was assessed with the use of mNUTRIC score. A multivariable Cox regression model to predict 28-day mortality was therefore developed including the mNUTRIC as a covariate. Internal validation was performed using the bootstrap resampling technique to reduce possible bias in the estimated risks. The performance of the prediction model was assessed via calibration and discrimination. A total of 98 critically ill COVID-19 patients with a median age of 66 years (56–73 IQR), 81 (82.7%) males were included in this study. A high nutritional risk (mNUTRIC ≥5 points) was observed in 41.8% of our critically ill COVID-19 patients while a low nutritional risk (mNUTRIC <5 points) was observed in 58.2%. Forty-five patients (45.9%) died within 28 days after ICU admission. In multivariable model after internal validation, mNUTRIC ≥5 (optimism adjusted HR 2.38, 95% CI 1.08–5.25, p = 0.02) and high-sensitivity C-reactive protein values (CRP) (optimism adjusted HR 1.02, 95% CI 1.01–1.07, p = 0.005) were independent predictors of 28-day mortality. A high prevalence of malnutrition as revealed by mNUTRIC was found in our critically ill COVID-19 patients once admitted in ICU. After adjustment for covariables, mNUTRIC ≥5 and CRP levels were independently associated with 28-day mortality in critically ill COVID-19 patients. The final model revealed good discrimination and calibration. Nutritional risk assessment is essential for the management of critically ill COVID-19 patients as well as for outcome prediction.
Keywords	C-reactive protein ; COVID-19 infection ; clinical nutrition ; malnutrition ; models ; mortality ; nutrition risk assessment ; prediction ; regression analysis ; risk
Language	English
Dates of publication	2022-04
Size	p. 202-209.
Publishing place	Elsevier Ltd
Document type	Article
ISSN	2405-4577
DOI	10.1016/j.clnesp.2022.02.014
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.

Li, Roger / Nocera, Luigi / Rose, Kyle M / Raggi, Daniele / Naidu, Shreyas / Mercinelli, Chiara / Cigliola, Antonio / Tateo, Valentina / Patanè, Damiano / Grass, G Daniel / Gilbert, Scott M / Sexton, Wade J / Bandini, Marco / Moschini, Marco / Briganti, Alberto / Montorsi, Francesco / Spiess, Philippe E / Necchi, Andrea

European urology oncology

2024

Abstract: Background: Recent progresses in the use of immune checkpoint inhibitor (ICI) have challenged the therapeutic standards in patients with muscle-invasive urothelial bladder carcinoma (MIBC).: Objective: To compare neoadjuvant pembrolizumab followed by ...

Abstract	Background: Recent progresses in the use of immune checkpoint inhibitor (ICI) have challenged the therapeutic standards in patients with muscle-invasive urothelial bladder carcinoma (MIBC). Objective: To compare neoadjuvant pembrolizumab followed by radical cystectomy (RC) versus neoadjuvant chemotherapy (NAC) and RC or upfront RC, according to cisplatin eligibility. Design, setting, and participants: We conducted two separate analyses for cisplatin-eligible and cisplatin-ineligible cT2-4N0M0 MIBC patients. We used a propensity score adjustment that relied on inverse probability of treatment-weighting (IPTW). Intervention: Pembrolizumab within the PURE-01 trial, and NAC and RC or upfront RC from a high-volume tertiary care referral center. Outcome measurements and statistical analysis: The primary endpoint in both analyses was event-free survival (EFS), defined as freedom from recurrence, and/or death from any cause indexed from the date of treatment initiation or RC. The secondary endpoints included EFS in propensity score-matched patients, pathologic response rate, and recurrence-free survival (RFS) after RC. Results and limitations: A total of 458 patients who underwent RC, with or without NAC, at Moffitt Cancer Center between October 2005 and October 2020, and 146 patients enrolled in PURE-01 were analyzed. In cisplatin-ineligible patients, EFS was superior in those receiving pembrolizumab (p < 0.001). The estimated 3-yr EFS was 77.8% (95% confidence interval [CI]: 63.5-95.2) for pembrolizumab and RC, and 36.1% (95% CI: 28.6-45.5) for upfront RC. EFS remained superior in those receiving neoadjuvant ICI (NICI) following IPTW (p < 0.001). In cisplatin-eligible patients, EFS was superior in those receiving pembrolizumab and RC (p < 0.001). The estimated 3-yr EFS was 86.9% (95% CI: 80.9-93.3) for pembrolizumab and 63.5% (95% CI: 56.5-71.4) for NAC. EFS remained superior in those receiving NICI following IPTW (p < 0.001). Pathologic responses and RFS in pembrolizumab-treated patients were also superior to those in NAC-treated patients. Results are limited by the retrospective nature of the study. Conclusions: In the first ever reported comprehensive comparison of outcomes between neoadjuvant ICI and NAC, followed by RC, or upfront RC, we report increased responses and improved oncologic outcomes with neoadjuvant ICI in patients with MIBC. Patient summary: We compared the results obtained from the use of pembrolizumab and radical cystectomy with standard-of-care treatments in patients with bladder carcinoma infiltrating the muscle layer. We reported increased response and survival rates possibilities with the use of immunotherapy, anticipating the possibility to set new therapeutic standards in these patients, pending the results of ongoing randomized studies.
Language	English
Publishing date	2024-01-05
Publishing country	Netherlands
Document type	Journal Article
ISSN	2588-9311
ISSN (online)	2588-9311
DOI	10.1016/j.euo.2023.12.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.

Longoni, Mattia / Scilipoti, Pietro / Re, Chiara / Rosiello, Giuseppe / Nocera, Luigi / Pellegrino, Francesco / Basile, Giuseppe / de Angelis, Mario / Quarta, Leonardo / Burgio, Giusy / Necchi, Andrea / Cigliola, Antonio / Chiti, Arturo / Picchio, Maria / Salonia, Andrea / Briganti, Alberto / Montorsi, Francesco / Moschini, Marco

BJU international

2024

Abstract: Objective: To assess the diagnostic performance of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) for bladder ... ...

Abstract	Objective: To assess the diagnostic performance of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) for bladder cancer (BCa). Materials and methods: This analysis was based on a cohort of 199 BCa patients undergoing RC and bilateral PLND between 2015 and 2022. Neoadjuvant chemotherapy (NAC) or immunotherapy (NAI) was administered after oncological evaluation. All patients received preoperative 18F-FDG PET/CT to assess extravesical disease. Point estimates for true negative, false negative, false positive, true positive, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of conventional imaging and PET/CT were calculated. Subgroup analysis in patients receiving neoadjuvant treatment was performed. Results: At preoperative evaluation, 30 patients (15.1%) had 48 suspicious nodal spots on 18F-FDG PET/CT. At RC and bilateral PLND, a total of 4871 lymph nodes (LNs) were removed with 237 node metastases corresponding to 126 different regions. Pathological node metastases were found in 17/30 (57%) vs 39/169 patients (23%) with suspicious vs negative preoperative 18F-FDG PET/CT, respectively (sensitivity = 0.30, specificity = 0.91, PPV = 0.57, NPV = 0.77, accuracy = 0.74). On per-region analysis including 1367 nodal regions, LN involvement was found in 19/48 (39%) vs 105/1319 (8%) suspicious vs negative regions at PET/CT, respectively (sensitivity = 0.15, specificity = 0.98, PPV = 0.40, NPV = 0.92, ACC = 0.90). Similar results were observed for patients receiving NAC (n = 44, 32.1%) and NAI (n = 93, 67.9% [per-patient: sensitivity = 0.36, specificity = 0.91, PPV = 0.59, NPV = 0.80, accuracy = 0.77; per-region: sensitivity = 0.12, specificity = 0.98, PPV = 0.32, NPV = 0.93, ACC = 0.91]). Study limitations include its retrospective design and limited patient numbers. Conclusions: In eight out of 10 patients with negative preoperative 18F-FDG PET/CT, pN0 disease was confirmed at final pathology. No differences were found based on NAC vs NAI treatment. These findings suggest that 18F-FDG PET/CT could play a role in the preoperative evaluation of nodal metastases in BCa patients, although its cost-effectiveness is uncertain.
Language	English
Publishing date	2024-04-15
Publishing country	England
Document type	Journal Article
ZDB-ID	1462191-5
ISSN	1464-410X ; 1464-4096 ; 1358-8672
ISSN (online)	1464-410X
ISSN	1464-4096 ; 1358-8672
DOI	10.1111/bju.16363
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.107: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 13: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The furanosidic scaffold of d-ribose: a milestone for cell life.

Del-Corso, Antonella / Cappiello, Mario / Moschini, Roberta / Balestri, Francesco / Mura, Umberto / Ipata, Piero Luigi

Biochemical Society transactions

2020 Volume 47, Issue 6, Page(s) 1931–1940

Abstract: The recruitment of the furanosidic scaffold of ribose as the crucial step for nucleotides and then for nucleic acids synthesis is presented. Based on the view that the selection of molecules to be used for relevant metabolic purposes must favor ... ...

Abstract	The recruitment of the furanosidic scaffold of ribose as the crucial step for nucleotides and then for nucleic acids synthesis is presented. Based on the view that the selection of molecules to be used for relevant metabolic purposes must favor structurally well-defined molecules, the inadequacy of ribose as a preferential precursor for nucleotides synthesis is discussed. The low reliability of ribose in its furanosidic hemiacetal form must have played ab initio against the choice of d-ribose for the generation of d-ribose-5-phosphate, the fundamental precursor of the ribose moiety of nucleotides. The latter, which is instead generated through the 'pentose phosphate pathway' is strictly linked to the affordable and reliable pyranosidic structure of d-glucose.
MeSH term(s)	Biochemical Phenomena ; Furans/metabolism ; Pentose Phosphate Pathway ; Reproducibility of Results ; Ribose/metabolism
Chemical Substances	Furans ; Ribose (681HV46001)
Language	English
Publishing date	2020-01-10
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	184237-7
ISSN	1470-8752 ; 0300-5127
ISSN (online)	1470-8752
ISSN	0300-5127
DOI	10.1042/BST20190749
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 944: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment.

Di Tano, Giuseppe / Moschini, Luigi / Loffi, Marco / Testa, Sophie / Danzi, Gian Battista

European journal of case reports in internal medicine

2020 Volume 7, Issue 7, Page(s) 1790

Abstract: Introduction: SARS-CoV-2 infection may predispose patients to thrombotic disease. Patients with COVID-19 pneumonia who are receiving non-vitamin K antagonists or direct oral anticoagulants for chronic disease are usually switched to heparin treatment ... ...

Abstract	Introduction: SARS-CoV-2 infection may predispose patients to thrombotic disease. Patients with COVID-19 pneumonia who are receiving non-vitamin K antagonists or direct oral anticoagulants for chronic disease are usually switched to heparin treatment during hospitalization. However, information about the most appropriate antithrombotic therapy after the acute infection phase is lacking. Case description: We report the case of a patient with chronic atrial fibrillation who was recently hospitalized for severe COVID-19 pneumonia. Four weeks after discharge he experienced an episode of an acute pulmonary embolism while on rivaroxaban therapy with adequate drug plasma levels, and in the absence of strong predisposing risk factors. Conclusion: This case highlights the risk of thrombotic complications after COVID-19 infection, raises some concern about their underlying mechanisms, and supports the use of effective anti-thrombotic therapy. Learning points: COVID-19 infection is associated with frequent thrombotic events.A pro-coagulative status could be triggered by the persistent inflammatory phase of the infection despite anticoagulation.Adequate antithrombotic therapy is necessary for the prevention of acute and later thrombotic complications and needs close monitoring.
Keywords	covid19
Language	English
Publishing date	2020-06-18
Publishing country	Italy
Document type	Journal Article
ISSN	2284-2594
ISSN (online)	2284-2594
DOI	10.12890/2020_001790
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.

Moschini, Luigi / Loffi, Marco / Regazzoni, Valentina / Di Tano, Giuseppe / Gherbesi, Elisa / Danzi, Gian Battista

Heart and vessels

2020 Volume 36, Issue 1, Page(s) 115–120

Abstract: Introduction: Most of the drugs associations that have been used to treat patients with SARS-CoV-2 infection increase the risk of prolongation of the corrected QT interval (QTc).: Objective: To evaluate the effects of an association therapy of ... ...

Abstract	Introduction: Most of the drugs associations that have been used to treat patients with SARS-CoV-2 infection increase the risk of prolongation of the corrected QT interval (QTc). Objective: To evaluate the effects of an association therapy of hydroxychloroquine (HY) plus ritonavir/darunavir (RD) or azithromycin (AZ) on QTc intervals. Methods: At the beginning of COVID-19 pandemic patients admitted to our hospital were treated with the empiric association of HY/RD; one week later the therapeutic protocol was modified with the combination of HY/AZ. Patients underwent an ECG at baseline, then 3 and 7 days after starting therapy. We prospectively enrolled 113 patients (61 in the HY/RD group-52 in the HY/AZ group). Results: A significant increase in median QTc was reported after seven days of therapy in both groups: from 438 to 452 ms in HY/RD patients; from 433 to 440 ms in HY/AZ patients (p = 0.001 for both). 23 patients (21.2%) had a QTc > 500 ms at 7 days. The risk of developing a QTc > 500 ms was greater in patients with prolonged baseline QTc values (≥ 440 ms for female and ≥ 460 ms for male patients) (OR 7.10 (95% IC 1.88-26.81); p = 0.004) and in patients with an increase in the QTc > 40 ms 3 days after onset of treatment (OR 30.15 (95% IC 6.96-130.55); p = 0.001). One patient per group suffered a malignant ventricular arrhythmia. Conclusion: Hydroxychloroquine with both ritonavir/darunavir or azithromycin therapy significantly increased the QTc-interval at 7 days. The risk of developing malignant arrhythmias remained relatively low when these drugs were administered for a limited period of time.
MeSH term(s)	Aged ; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/therapeutic use ; Azithromycin/adverse effects ; Azithromycin/therapeutic use ; COVID-19/drug therapy ; COVID-19/epidemiology ; Darunavir/adverse effects ; Darunavir/therapeutic use ; Electrocardiography/drug effects ; Enzyme Inhibitors/therapeutic use ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Long QT Syndrome/chemically induced ; Long QT Syndrome/physiopathology ; Male ; Middle Aged ; Ritonavir/adverse effects ; Ritonavir/therapeutic use ; SARS-CoV-2
Chemical Substances	Anti-Bacterial Agents ; Enzyme Inhibitors ; Hydroxychloroquine (4QWG6N8QKH) ; Azithromycin (83905-01-5) ; Ritonavir (O3J8G9O825) ; Darunavir (YO603Y8113)
Keywords	covid19
Language	English
Publishing date	2020-07-16
Publishing country	Japan
Document type	Journal Article
ZDB-ID	89678-0
ISSN	1615-2573 ; 0910-8327 ; 0935-736X
ISSN (online)	1615-2573
ISSN	0910-8327 ; 0935-736X
DOI	10.1007/s00380-020-01671-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2049: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation.

Di Tano, Giuseppe / Dede, Meghi / Pellicelli, Irene / Martinelli, Enrico / Moschini, Luigi / Calvaruso, Elva / Danzi, Gian Battista

Journal of thrombosis and thrombolysis

2021 Volume 53, Issue 3, Page(s) 576–580

Abstract: Thrombotic complications are common in patients with severe COVID-19 pneumonia with important consequences on the diagnostic and therapeutic management. We report a consecutive series of five patients on long-term oral anticoagulation therapy who ... ...

Abstract	Thrombotic complications are common in patients with severe COVID-19 pneumonia with important consequences on the diagnostic and therapeutic management. We report a consecutive series of five patients on long-term oral anticoagulation therapy who presented to our hospital for severe COVID-19 pneumonia associated with segmental acute pulmonary embolism despite adherence to therapy and with an adequate anticoagulant range at the time of the event. Four patients were receiving a direct oral anticoagulant (two with edoxaban, one with rivaroxaban and one with apixaban) and one patient a vitamin K antagonist. No significant thrombotic risk factors, active cancer, or detectable venous thromboembolism were present. In all cases, elevated d-dimer and fibrinogen levels with a parallel rise in markers of inflammation were documented. The combination of these findings seems to support the hypothesis that considers the local vascular damage determined by severe viral infection as the main trigger of thrombi detected in the lungs, rather than emboli from peripheral veins.
MeSH term(s)	Anticoagulants/therapeutic use ; COVID-19/complications ; COVID-19/drug therapy ; Humans ; Pulmonary Embolism/drug therapy ; Pulmonary Embolism/etiology ; Rivaroxaban/therapeutic use ; Venous Thromboembolism/chemically induced ; Venous Thromboembolism/etiology
Chemical Substances	Anticoagulants ; Rivaroxaban (9NDF7JZ4M3)
Language	English
Publishing date	2021-10-27
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1230645-9
ISSN	1573-742X ; 0929-5305
ISSN (online)	1573-742X
ISSN	0929-5305
DOI	10.1007/s11239-021-02589-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4352: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito